Concepedia

Judit Anido

JA

Statistics

Publications

10

Citations

2.8K

H-Index

10

Active since

2001

Affiliations

Vall d'Hebron Hospital Universitari(Current)

Universitat Autònoma de Barcelona

Institució Catalana de Recerca i Estudis Avançats

Vall d'Hebron Institute of Oncology

Judit Anido is an author at Vall d'Hebron Hospital Universitari specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2001–2022

10

Publications

10

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

Maurizio Scaltriti, Federico Rojo, Alberto Ocaña et al. · JNCI Journal of the National Cancer Institute · 2007 · 881 citations · Full text

, , +17

TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

Judit Anido, Andrea Sáez‐Borderías, Alba Gonzàlez-Juncà et al. · Cancer Cell · 2010 · 576 citations · Full text

, , +14

TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma

Silvia Peñuelas, Judit Anido, Rosa M. Prieto-Sánchez et al. · Cancer Cell · 2009 · 524 citations · Full text

, , +14

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

Joan Albanell, Jordi Codony‐Servat, Federico Rojo et al. · PubMed · 2001 · 276 citations

, , +17

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Judit Anido, Pablo Matar, Joan Albanell et al. · PubMed · 2003 · 249 citations

, , +17

1–5 of 10